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Abstract

ARTICLE

Background: Personalized genomic classifiers have transformed the management of prostate cancer (PCa) by identifying the
most aggressive subsets of PCa. Nevertheless, the performance of genomic classifiers to risk classify African American men is
thus far lacking in a prospective setting. Methods: This is a prospective study of the Decipher genomic classifier for National
Comprehensive Cancer Network low- and intermediate-risk PCa. Study-eligible non–African American men were matched to
African American men. Diagnostic biopsy specimens were processed to estimate Decipher scores. Samples accrued in
NCT02723734, a prospective study, were interrogated to determine the genomic risk of reclassification (GrR) between conventional clinical risk classifiers and the Decipher score. Results: The final analysis included a clinically balanced cohort of 226
patients with complete genomic information (113 African American men and 113 non–African American men). A higher
proportion of African American men with National Comprehensive Cancer Network–classified low-risk (18.2%) and favorable
intermediate-risk (37.8%) PCa had a higher Decipher score than non–African American men. Self-identified African American
men were twice more likely than non–African American men to experience GrR (relative risk [RR] ¼ 2.23, 95% confidence
interval [CI] ¼ 1.02 to 4.90; P ¼ .04). In an ancestry-determined race model, we consistently validated a higher risk of reclassification in African American men (RR ¼ 5.26, 95% CI ¼ 1.66 to 16.63; P ¼ .004). Race-stratified analysis of GrR vs non-GrR tumors
also revealed molecular differences in these tumor subtypes. Conclusions: Integration of genomic classifiers with clinically
based risk classification can help identify the subset of African American men with localized PCa who harbor high genomic
risk of early metastatic disease. It is vital to identify and appropriately risk stratify the subset of African American men with
aggressive disease who may benefit from more targeted interventions.

Prostate cancer (PCa) is one of the leading cancers and impacts
millions of men in the United States and around the world, with
etiologies ranging from socioeconomic factors to neighborhood
characteristics and underlying genomics (1). Though PCa affects

men of different races and ethnicities, African American men
are disproportionately impacted by higher incidence and
increased PCa-related mortality (2). However, few prospective
studies maximize minority recruitment to provide an unbiased
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Methods
Study Design, Eligibility Criteria, and Matching
This was a multisite prospective study (NCT02723734) of the
Decipher score among self-reported African American men and
non–African American men. Before study activation, full institutional and local site institutional review board approval was
obtained. Enrolled patients had to meet the following inclusion
criteria: aged 18 years and older; Eastern Cooperative Oncology
Group Performance Status 0-1 or Karnofsky Performance Status
greater than 70; have pathologically and histologically confirmed NCCN-classified low- or intermediate-risk PCa (low risk
defined as biopsy Gleason score 6 [3 þ 3] along with pretreatment prostate-specific antigen [PSA] level <10 ng/mL and T
stage T1c-T2a; intermediate risk defined as biopsy Gleason
score 7 with PSA level 10ng/mL or <20 ng/mL, or T stage T2c);
and be undergoing their first line of treatment. First-line treatment included radical prostatectomy (RP) or definitive radiation
therapy (RT) with or without short-term androgen deprivation
therapy. Patients who were identified for active surveillance
(AS) after diagnostic biopsy or on AS for more than 6 months
after diagnosis were excluded from recruitment. Lastly, patients

Data Collection
Major variables included self-identified race, age at diagnosis,
pretreatment PSA, PPB (calculated by dividing cores positive by
total cores evaluated), biopsy Gleason score, NCCN-defined risk
categories, and CAPRA. Methods for deriving CAPRA are defined
in Cooperberg et al. (9) The NCCN intermediate-risk group was
subdivided as favorable intermediate risk and unfavorable
intermediate risk. Favorable intermediate risk was defined as
the presence of 1 intermediate risk factor alongside biopsy
Gleason score (3 þ 4) and no more than 50% of PPB, whereas
unfavorable intermediate risk was defined by having more than
1 intermediate-risk factor, biopsy Gleason score (4 þ 3), or more
than 50% PPB. For the subset of patients who underwent RP,
pathology information, including pathologic Gleason score and
adverse pathologic features (extracapsular extension, surgical
margins, seminal vesicle invasion, and lymph node involvement), was also collected. Additionally, Decipher scores were
obtained along with the comprehensive expression-based transcriptomic signatures for each patient from the genomic
resource information database repository, a database of gene
expression signatures and tumor transcriptome (Veracyte Inc,
California, USA). Decipher score ranges from 0 to 1 and is categorized as low (<0.45), intermediate (0.45-0.60), and high
(>0.60) risk. Additional details on genomic signatures used in
this analysis are provided in Supplementary Methods (available
online). Lastly, ancestry determination was performed on the
consented patients at the University of Minnesota Genomics
Center (Supplementary Methods, available online) (10).

Clinical Outcome Assessment
Genomic risk of reclassification (GrR) was used as a clinical outcome to identify the subset of NCCN-classified low-risk and
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with prior PCa-related treatment were also considered ineligible. Additional details on recruitment are provided in the
Supplementary Methods (available online).
To maximize minority enrollment, study-eligible African
American men were accrued first, and then clinically matched
non–African American men were subsequently enrolled.
Matching was performed to balance the baseline clinical difference between race groups. Non–African American men were
matched to African American men on age, PSA level at diagnosis, biopsy Gleason score, clinical stage, and total percent of
positive biopsy (PPB) cores. Participants were then stratified
based on their treatment selection for RP vs RT with or without
short-term androgen deprivation therapy. No treatment intervention beyond the standard of care was permitted, and therefore, patients were able to choose their definitive treatment
option through shared decision making based on physician recommendations. The intent was to enroll early localized PCa
defined as low- and intermediate-risk patients with multiple
cores positive (high disease burden) to minimize accruing
patients who would select AS and be excluded from study. A
total of 276 patients were approached for participation in the
VANDAAM study, with 243 patients (125 African American men
and 118 non–African American men) enrolling in the study. The
CONSORT diagram provides a detailed overview of the study
cohort (see Figure 1). Though this study does not report on the
primary endpoint of NCT02723734 (2-year failure rate), it
presents the correlative assessment of clinical risk classifiers
and the Decipher score on the samples accrued in this trial.
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assessment of the genomic processes that underscore the disparity landscape of PCa (1). In the era of precision medicine, personalized genomic classifiers, such as the Decipher score, have
transformed the management of PCa by aiding in the detection
of aggressive subsets of PCa (3). The Decipher score is a validated 22-gene–based genomic classifier that predicts risk of
metastasis and may offer a robust alternative to reduce disparity gaps, especially among the subset of African American men
who are likely to experience increased disease severity (3-5).
Though the Decipher score was developed using a predominantly White cohort, its utility in retrospective studies has been
comparable between African American men and non–African
American men (4). More important, Howard et al. (4), in their
recent study, showed that it had relatively similar accuracy in
predicting metastasis between African American men and non–
African American men. Therefore, a prospective evaluation of
the Decipher score would aid in identifying aggressive African
American men tumor subtypes that may benefit from targeted
interventions and treatment strategies. Considering that conventional clinical risk classifiers, such as the National
Comprehensive Cancer Network (NCCN) classification and the
Cancer of the Prostate Risk Assessment (CAPRA), have also been
shown to be suboptimal in African American men, particularly
for low- and intermediate-risk PCa, the integration of conventional clinical risk classifiers with genomic classifiers may offer
a robust improvement in risk stratifying and appropriately
managing PCa patients (6,7). Emerging work has also shown
that early PCa may harbor genomically aggressive subtypes,
and these subsets are unlikely to be captured by clinical risk
classifiers alone (6,8). Therefore, evaluating genomic classifiers
in conjunction with clinical risk classifiers to identify patients
with aggressive disease within a minority-targeted prospective
study will elucidate their clinical utility across different subpopulations. Therefore, samples from the NCT02723734 prospective study were genomically interrogated to evaluate whether
the integration of Decipher score with clinical risk classifiers
can distinguish subsets of men with early localized PCa who
may harbor aggressive disease, particularly among African
American men who experience the greatest burden of PCa.
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NCT02723734

Total approached
n = 276
African american men = 143
Non–african american men = 133
Non consented
n = 33

QC failed (No genomic informaon)
n = 17
Transcriptomic data
n = 226
African american men = 113
Non–african american men = 113

Low Risk
n = 18
African american men = 11
Non–african american men = 7

Favorable intermediate risk
n = 74
African american men = 37
Non–african american men = 37

Unfavorable intermediate risk
n = 134
African american men = 65
Non–african american men = 69

Ancestry
n = 14
African american men = 7
Non–african american men = 7

Ancestry
n = 58
African american men = 28
Non–african american men = 30

Ancestry
n = 99
African american men = 42
Non–african american men = 57

ARTICLE

Figure 1. Consort diagram of patient enrollment among the total enrolled participants (n ¼ 243); 226 passed the quality control and had complete genomic information
available. aBlood draw for ancestry genotyping was carried out for 184 of 243 enrolled patients. Of the 184 samples with ancestry information, 171 patients also had
complete genomic information available. QC ¼ Quality Control.

favorable intermediate-risk patients who harbored genomic risk
of metastasis. GrR status was derived using the presence of a
high Decipher score in low-risk and favorable intermediate-risk
categories. Non-GrR tumors were defined as low-risk and favorable intermediate-risk patients with Decipher scores of 60 or
lower.

Statistical Analysis
Baseline and clinical characteristics between race groups were
compared using Pearson v2 and Fisher exact tests. Similar statistical tests of categorical comparisons were used to assess the
relationship between NCCN and CAPRA risk categories with the
Decipher score. To model the GrR among low-risk and favorable
intermediate-risk patients, we estimated the relative risk (RR)
using a log-binomial model. We also validated preceding selfidentified race model estimates by using ancestry-determined
race categories. Considering the age differences between race
groups, both models were also adjusted for age at diagnosis. In
addition, we also evaluated the race-stratified nonlinear association of age with overall high Decipher score (>.60) and GrR
tumors in a nonlinear binomial spline regression model using a

B-spline function with 5 degrees of freedom. Probability of GrR
tumors and high Decipher score were then estimated and plotted to compare between African American men and non–
African American men. We also estimated the risk of pathologic
upgrading of Gleason score using a log-binomial model within
the subset of patients who received RP. Lastly, precomputed
expression-based genomic signatures between race groups
were compared using the Wilcoxon rank-sum test. The analyses
were conducted in SAS 9.4 and R 1.3.1. All the tests were 2-sided,
and cutoff values were no more than .05.

Results
Baseline and Clinical Characteristics
A detailed comparison of demographic and clinical variables for
all the matched evaluable patients with complete genomic
information (n ¼ 226) is presented in Table 1. There were no differences between African American men and non–African
American men for pretreatment PSA (P ¼ .26), biopsy Gleason
score (P ¼ .64), PPB (P ¼ .46), NCCN risk (P ¼ .60), CAPRA (P ¼ .91),
biopsy Decipher score (P ¼ .62), or primary treatment selection
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Total enrolleda
n = 243
African american men = 125
Non–african american men = 118
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Characteristic

61 (55-67)

65 (59-70)

12 (11)
101 (89)

5 (4.4)
108 (96)

6.9 (5.1, 8.8)

6.3 (4.3, 8.4)

44 (39)
45 (40)
24 (21)

51 (45)
42 (37)
20 (18)

13 (12)
67 (59)
33 (29)
5 (4-7)

9 (8.0)
68 (60)
36 (32)
6 (4-8)

36 (32)
77 (68)

31 (27)
82 (73)

11 (9.7)
37 (33)
65 (58)

7 (6.2)
37 (33)
69 (61)

Pa
.005
.07

.26
.61

.64

.11
.46

.60

.91
21 (19)
70 (62)
22 (19)

20 (18)
73 (65)
20 (18)
.62

47 (42)
27 (24)
39 (35)

46 (41)
33 (29)
34 (30)

41 (36)
41 (36)
25 (22)
6 (5.3)

41 (36)
47 (42)
21 (19)
4 (3.5)

.76

a

Wilcoxon rank sum test for numeric and Pearson v2 test for categorical varia-

bles. ADT ¼ androgen deprivation therapy; CAPRA ¼ Cancer of the Prostate Risk
Assessment; IQR ¼ interquartile range; NA ¼ not available; NCCN ¼ National
Comprehensive Cancer Network; PPB ¼ positive percentage biopsy; PSA ¼ prostate-specific antigen.
b

Decipher score is categorized as low risk (<0.45), intermediate risk (0.45-0.60),

and high risk (>0.60).

(P ¼ .76) (Table 1). Despite rigorous targeted matching, African
American men enrolled in the study were relatively younger
than non–African American men (aged 61 vs 65 years; P ¼ .005).

Genomic Risk of Reclassification in African American
Men
We compared GrR between clinical and genomic risk classifiers
from samples with complete genomic information (113 African
American men and 113 non–African American men samples). A
higher proportion of African American men with NCCNclassified low risk (18.2%) and favorable intermediate risk
(37.8%) harbored a higher genomic risk of metastasis than non–
African American men (Figure 2, A and B). More important,
among non–African American men, no low-risk patients were

Ancestry Validation of Self-Reported Race Model
We performed ancestry evaluation on patients who consented
for blood collection (n ¼ 184). For ancestry determination, 93
self-identified African American men and 91 self-identified
non–African American men were analyzed. To optimize
ancestry-base race categorization, we explored overall ancestry
distribution and overlayed it with self-defined race groups.
Median-based ancestry cutoff captured nearly 97% (n ¼ 90) of
self-identified African American men, with only 3% (n ¼ 3)
being misclassified as having shared European ancestry
(Figure 4, A). We therefore decided to apply a more stringent
ancestry quotient cutoff to limit the self-identified African
American men who may share borderline ancestry. Figure 4, B
shows that 91.4% (n ¼ 85) of self-identified African American
men patients had more than 50% African ancestry, and 8.6%
(n ¼ 8) self-identified African American men patients were genotyped as having European ancestry. Because ancestry determination was not performed for all patients, we modified the
self-identified race model 1 and subsequently developed model
2, which only included patients who had ancestry information
available. This allowed for direct comparison of self-identified
race estimates to ancestry-based race estimates. GrR from selfidentified race model 2 was consistently higher in African
American men than non–African American men (RR ¼ 4.13,
95% CI ¼ 1.30 to 13.04; P ¼ .01) (Table 2, model 2). Finally, we
estimated the presence of GrR using only ancestry-determined
race categories in model 3 and observed nearly 5 times the risk
of reclassification among low-risk and favorable intermediaterisk African American men (RR ¼ 5.26, 95% CI ¼ 1.66 to 16.63;
P ¼ .004) (Table 2, model 3).

Molecular Basis of GrR in African American Men
We evaluated the molecular underpinnings of GrR within the
low-risk and favorable intermediate-risk subset of African
American men. We used precomputed gene expression
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Median age (IQR), y
Age group, No. (%)
Younger than 50
50 and older
Pretreatment PSA, ng/mL
Median (IQR)
PSA categories, No. (%)
0-6 ng/mL
>6-10 ng/mL
>10-20 ng/mL
Biopsy Gleason score, No. (%)
3þ3
3þ4
4þ3
Median No. of positive
cores (IQR)
PPB category, No. (%)
<34
34
NCCN risk, No. (%)
Low risk
Favorable risk
Unfavorable risk
Biopsy CAPRA, No. (%)
0-2
3-5
6-10
Decipher (biopsy)
category, No. (%)b
Low risk
Int risk
High risk
Treatment type, No. (%)
Prostatectomy
Radiation (no ADT)
Radiation (with ADT)
NA

African
Non–African
American men American men,
(n ¼ 113)
(n ¼ 113)

genomically reclassified. When we modeled the GrR from selfreported race (Table 2, model 1), African American men were
more than twice as likely to experience reclassification
(RR ¼ 2.23, 95% confidence interval [CI] ¼ 1.06 to 4.90; P ¼ .04)
(Table 2). We also compared the univariate association between
baseline clinical variables and GrR and did not observe any statistically significant impact of these variables on the GrR
(Supplementary Table 1, available online). Similarly, when compared with CAPRA, 19% of African American men were reclassified to a higher genomic risk subcategory within the low-risk (02) group (P ¼ .01) compared with only 10% non–African
American men (P ¼ .009) (Figure 2, C and D). African American
men with high genomic risk were also younger than non–
African American men (P ¼ .01) (Figure 3, A). When analyzed in
the spline model, a nonlinear association between age and
Decipher score was observed, with younger African American
men having increased probability of a higher Decipher score
(Figure 3, B). Similarly, probability of GrR was also higher among
younger African American men than non–African American
men (Figure 3, C). Lastly, within the subset of patients who
elected for RP, African American men were also more likely to
experience a Gleason score upgrade (RR ¼ 3.25, 95% CI ¼ 1.15 to
9.11; P ¼ .02) (Supplementary Table 2, available online), though
no differences in other pathologic features were noted
(Supplementary Table 3, available online).
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Table 1. Cohort characteristics (n ¼ 226)
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Decipher risk

A

High risk

Int risk

B

African american men

P = .04

100

Low risk

Non–african american men

100

0

18.2

13.5
50

32.3
72.7

25

18.9
39.1

75

Proportion

9.1

28.6

35.4

37.8
50

24.7
71.4

25

48.7

43.3

36.2

32.3
0

0
Low risk
(n = 11)

Favorable risk
(n = 37)

Unfavorable risk
(n = 65)

Low risk
(n = 7)

NCCN risk

C

D

Non–african american men

P = .01

100

19.1

Proportion

75

9.5

45.4

24.3

50

36.4

71.4
25

P = .009
10
27.4

75

Proportion

35.7

Unfavorable risk
(n = 69)

NCCN risk

African american men

100

Favorable risk
(n = 37)

60
32.9

50
10
25

40

35

55
39.7

30

18.2

ARTICLE

0

0
0−2
(n = 21)

3−5
(n = 70)

6 − 10
(n = 22)

CAPRA

0−2
(n = 20)

3−5
(n = 73)

6 − 10
(n = 20)

CAPRA

Figure 2. Comparison between clinical risk classifier and race group in transcriptomic data (n ¼ 226; African American men, n ¼ 113; and non–African American men,
n ¼ 113). A) Comparison of NCCN risk groups and Decipher score in African American men. B) Comparison of NCCN risk groups and Decipher score in non–African
American men. C) Comparison of CAPRA risk categories and Decipher score in African American men. D) Comparison of CAPRA risk categories and Decipher score in
non–African American men. CAPRA ¼ Cancer of the Prostate Risk Assessment; Int ¼ intermediate; NCCN ¼ National Comprehensive Cancer Network.

signatures available within the genomic resource information
database repository and evaluated their distribution between
GrR and non-GrR African American men tumors. Tumors from
African American men who experienced reclassification exhibited higher basal-like characteristics and had lower rates of
androgen receptor (AR) activity. We applied Zhang et al. (11) gene
expression signature for classification of basal-like tumors and
found that genomically reclassified tumors within African
American men had higher basal-like gene expression (P ¼ .009;
Figure 5). Consistently, GrR tumors also had a lower score for
luminal tumor subtypes (P < .001; Figure 5) (12). To assess AR
activity, we used the hallmark AR signature from Liberzon et al.
(13) and AR activity score from Spratt et al. (14) and showed that
GrR tumors in African American men consistently had lower AR
activity than non-GrR tumors of African American men (Figure 5).

Lastly, we evaluated the enrichment of immune content in
African American men tumors with GrR and observed that these
tumor subsets were enriched for 190 immune-mediated gene
expression markers (P ¼ .04) (15). Furthermore, we also used an
estimate-based signature of immune estimate and showed that
GrR tumors from African American men indeed had higher
immune enrichment (Figure 5) (16). Considering that the proportion of GrR tumors were much lower in non–African American
men, reclassified tumors from non–African American men did
not reveal similar molecular features to those seen in African
American men tumors. Finally, reclassified tumors among
African American men and non–African American men had
higher expression of macrophage signatures; however, both
groups consistently had lower expression of the regulatory T-cell
signature (Figure 5) (17,18).
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Proportion

75

37.8

P = .05
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Discussion
This prospective study used a clinically balanced cohort of
African American men and non–African American men and
showed that a subset of African American men harbor genomically aggressive PCa, which may not be detected with conventional clinical classifiers. Therefore, results from this study
support the integration of personalized biomarkers with

Table 2. Log binomial regression to estimate the risk of genomic
reclassification within low-favorable intermediate risk patients
Modela

Race

Model 1

Model 2c

Model 3d

Self-reported race
African American men
Non–African American men
Self-reported race
African American men
Non–African American men
Ancestry-derived race
African ancestry
European ancestry

RR (95% CI)

P

2.23 (1.02 to 4.90)
1 (Referent)

.04

4.13 (1.30 to 13.04)
1 (Referent)

.01

5.26 (1.66 to 16.63)
1 (Referent)

.004

a

All models are adjusted age at diagnosis and developed in low-favorable inter-

mediate risk patients. CI ¼ confidence interval; RR ¼ relative risk.
b
Model 1 estimates the self-reported race–based relative risk of genomic reclassification for all the patients.
c

Model 2 estimates the self-reported race–based relative risk of genomic reclas-

sification for the patients with ancestry determination completed.
d
Model 3 with ancestry-derived race was carried out in patients who underwent
ancestry determination.

A

Non-african american men
P = .002

African american men
P = .01

P = .82

70

ARTICLE

Age, y

80

60
50
40
Low risk

Int risk
Decipher score

High risk

B

C

0.75
Overall

African american men

0.25

Probability of genomic reclassification

Probability of high decipher score

1.00

0.50

African american men

0.20

0.15
Overall

0.10

0.05

Non–african american men

Non–african american men

0.00

0.00
50
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b

conventional clinical risk classifiers, particularly for African
American men, to optimize timely detection of genomically
aggressive
PCa
and
guide
appropriate
treatment
recommendations.
Timely detection of aggressive tumor subtypes portends
favorable prognoses and is associated with improved outcomes
(7). Considering that clinical risk classifiers, primarily the NCCN
risk groups, are a mainstay in PCa risk stratification and management, their ability to discern these tumor subtypes across
racial subgroups is vital (7). However, clinical risk classifiers
alone do not offer optimal detection of these aggressive subtypes because they exclusively rely on clinicopathologic features and do not account for the genomic diversity of prostate
tumors (6,7). An earlier study by Spratt et al. (6) demonstrated
that integration of a genomic classifier into clinical risk classifier outperformed both NCCN and CAPRA classifications in the
prediction of long-term outcomes. This is highly relevant to
African American men whose tumors exhibit high genomic variability (8,19,20). Prior retrospective studies have revealed that
PCa in African American men with low-risk disease may often
show higher Decipher scores and are more likely to experience
pathological upgrading compared with non–African American
men (8,21,22). An alternative approach is to use a multiparametric magnetic resonance imaging (mp-MRI) of the prostate and
pelvis, which offers enhanced staging accuracy for African
American men and non–African American men, but its utilization for PCa remains disparate, with African American men less
likely to undergo mp-MRI (23,24). Additionally, mp-MRI–based
risk classification of PCa does not account for genomic distinctions in tumor characteristics. Therefore, genomic classification

60

70

Age

80

50

60

70

80

Age

Figure 3. Impact of age on Decipher score distribution and genomic reclassification. A) Age in years is compared between race groups across Decipher score categories.
B) A nonlinear binomial model with B-spline showing the probability of higher Decipher score across race groups by increasing age in years. C) A nonlinear binomial
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may offer a robust alternative to identify specific subsets of
patients with disease that is likely to metastasize despite being
classified as low risk or favorable intermediate risk by conventional clinical risk classifiers. Recently, Feng et al. (25) validated
genomic classifiers in a prospective randomized trial (RTOG
9601) to predict androgen deprivation therapy response among
patients. Their findings suggested that genomic classifiers may
help personalize shared decision making to weigh the absolute
benefit of androgen deprivation therapy in addition to primary
therapy. Therefore, using genomic-based precision biomarkers
alongside clinical risk classifiers may also aid clinicians to further personalize treatment decision making and identify
patients who may benefit from additional therapeutic
interventions.
Considering that African American men are known to experience a higher burden of PCa at a much earlier age, we further
evaluated age-specific differences in Decipher scores and GrR
tumors (1). Our nonlinear spline model suggested that younger
African American men harbored higher genomic risk of metastasis, which may underlie the presence of GrR tumors in this
group. These results may inform the clinical recommendations
pertaining to early detection of aggressive PCa and support the
use of additional diagnostic tools to appropriately stage patients
for optimal care.
To understand the genomic characteristics of GrR tumors,
we investigated the expression-based signature that may be
enriched within these tumors. In a race-stratified analysis of
GrR vs non-GrR tumors, we observed a relative difference in the
precomputed signatures that underlie AR biology, basal and
luminal cell lineages, and overall immune cell enrichment. AR
activity plays a vital role in tumorigenesis and regulation of
DNA repair pathways (26). Considering that DNA repair and AR
biology can also modulate response to RT, our results may offer

insights into RT response of GrR tumors from African American
men (26). Furthermore, GrR tumors among African American
men also exhibited higher enrichment of a signature estimating
basal cell lineage than non-GrR tumors, which is consistent
with the earlier work of Zhang et al. (11). Lastly, we also identified a higher immune cell abundance within GrR tumors from
African American men, signifying the role of the immune repertoire within the prostate tumor microenvironment of genomically aggressive subtypes. Consistently, a number of studies in
PCa have shown that higher immune content enrichment in
PCa is associated with an elevated risk of poor outcomes (27,28).
Additionally, immune content can be evaluated alongside the
Decipher score to identify subtypes that are harbingers of lethal
outcomes (27). Emerging research has revealed the presence of
a distinct immune microenvironment in PCa of African
American men that is enriched in inflammatory markers (19).
Whether such immune repertoire within prostate tumors of
African American men could underlie observed higher prevalence of GrR tumors in this subset remains unexplored. This
study does not suggest that observed differences in aforementioned signatures drive disparities in African American men;
instead, it shows that GrR tumors of African American men are
genomically distinct and that further validation may be warranted to assess their race-specific functional role in the progression of these genomically aggressive tumor subtypes.
This prospective study reports that African American men
may benefit from the integration of precision biomarkers and
clinical risk classifiers to optimize risk stratification. Detection
of these tumor subtypes within early localized PCa may help
clinicians select the subset of patients who are likely to benefit
from additional therapeutic interventions. This work has a few
limitations. First, like other clinical trials, the African American
men enrolled in this study may be less representative of
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minorities across the United States; African American men participants may have higher health-care–seeking behavior, socioeconomic status, and overall willingness to participate in
clinical trials compared with the general population (1). Second,
despite rigorous matching, a significant age gap persisted
between race groups, emphasizing the role of age in studying
minority populations. However, we attempted to achieve a clinically balanced cohort to facilitate a first-of-its-kind genomic
study in a prospective manner. Additionally, using ancestryinformed markers of race further strengthens our findings from
a self-identified race model and obviates any resulting biases.

Overall, our findings show that conventional clinical risk classifiers models may be suboptimal in assessing true disease
severity in a subset of African American men who are likely to
have a high genomic risk for distant metastasis.
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